Compare Recursion Pharmaceuticals Inc (RXRX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Global X Uranium ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Global X Uranium ETF trades at $46.3. The key difference: Global X Uranium ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | URA | |
|---|---|---|
Market Cap | $1.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $61.81 |
52-Week Low | $2.84 | $37.52 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
URA trades at $47.50, up 3.13% today amid bullish technical signals from moving averages and positive momentum indicators. The ETF benefits from growing nuclear energy demand driven by AI power needs and recent government funding commitments. However, key financial ratios remain undisclosed, limiting fundamental visibility into underlying holdings.
Outlook remains positive given nuclear energy's role in AI infrastructure and policy support, but investors face risks from uranium price volatility and ETF concentration. The technical setup suggests near-term resistance at $48-$50, with support at $45-$47.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
